Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

Andres Forero-Torres, Nancy Bartlett, Anne Beaven, Han Myint, Sunita Nasta, Donald W. Northfelt, Nancy C. Whiting, Jonathan G. Drachman, Albert F. Lobuglio, Craig H. Moskowitz

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Dacetuzumab, a CD40-targeted, humanized antibody, mediates antitumor activity through effector cell functions and direct apoptotic signal transduction. Preclinical studies demonstrated synergistic activity between dacetuzumab, gemcitabine and rituximab against non-Hodgkin lymphoma in vivo. A phase 1b safety/efficacy study of dacetuzumab in combination with rituximab and gemcitabine was conducted in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received dacetuzumab at doses of 8 or 12 mg/kg IV weekly with rituximab (375 mg/m2 IV weekly in cycle 1, then every 28 days) and gemcitabine (1000 mg/m2 IV, days 1, 8 and 15, or days 1 and 15). Thirty-three patients with a median age of 67 years were enrolled. Common adverse events (≥15%) were grade 1/2 cytokine release syndrome, nausea, fatigue, thrombocytopenia, headache, decreased appetite, dyspnea, neutropenia, pyrexia, anemia, diarrhea, edema, constipation and cough. Dacetuzumab-related grade 3/4 adverse events occurred infrequently. Six of 30 evaluable patients achieved a complete response (CR) and eight a partial response (PR) per investigator assessment for an overall response rate (ORR) of 47%.

Original languageEnglish (US)
Pages (from-to)277-283
Number of pages7
JournalLeukemia and Lymphoma
Volume54
Issue number2
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Keywords

  • Antibody-based immunotherapy
  • Chemotherapeutic approaches
  • Lymphoma and Hodgkin disease

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Forero-Torres, A., Bartlett, N., Beaven, A., Myint, H., Nasta, S., Northfelt, D. W., Whiting, N. C., Drachman, J. G., Lobuglio, A. F., & Moskowitz, C. H. (2013). Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leukemia and Lymphoma, 54(2), 277-283. https://doi.org/10.3109/10428194.2012.710328